Eva Hlaučová, Eva Hyrdelová, Oľga Chromá
Defects of hemocoagulation are severe complications in patients with critical neoplasmatic diseases. Hypercoagulation status is common clinical and laboratory finding that occur in about 15 % of patients. There is a gradation of chronic inflammation during neoplasmatic disease with activation of immunity system and increased synthesis of cytokines, oncomarkers and acutephase proteins. High concentrations of fibrinogen, thrombocytosis and proinflammation cytokines activate hypercoagulation condition that manifests like thrombosis of veins, migrating thromboflebitis and thromboembolism. Except that the cause of thromboembolism is also a harm of vessel-wall, tumor invasion to the vessel-wall, compression of vessel by tumor, deceleration of blood flow, production of procoagulation substances inside the tumor and activation of thrombocytes by tumor. In prevention and therapy low-molecular-weight heparin is commonly used, that can have synergistic and supporting effect with antineoplasmatic therapy.